For bone diseases, e.g. rachitism, paget's disease (A61P19/08)

Method of treating delayed union and unfused fractures of long bones

Method involves using calcium-phosphate coated (CPC) implants with the coating formed of calcium phosphate globules 0.8-150 mcm in diameter and consisting of spherolith-like crystals forming a coating surface macrorelief with a pore size falling within the range of 5-100 mcm. The used CPC is characterised by porosity 50-60%, thickness 10-40 mcm. The CPC composition contains, vol %: hydroxyapatite - 66-72, titanium - 1.3-1.8, titanium dioxide - 2.0-2.4, the rest - an amorphous phase. The amorphous phase of the CPC consists of at least one compound specified in a group including calcium dihydrophosphates, calcium hydroxyphosphates, calcium titanate, calcium titanium diphosphate.

Pth-containing therapeutic/prophilactic anti-osteoporosis agent, characterised by weekly introduction of pth in standard dose of 100-200 units

Invention relates to medicine and deals with a method of treatment or prevention of osteoporosis, including introduction to a subject requiring it of a medication which contains PTH as an active ingredient, where PTH is introduced one time per week in a standard dose of 200 units, and the subject satisfies all of the following conditions: age 65 years and older, prevailing bone fractures, bone density lower than 80% of the average density of the young adult and/or a degree of bone atrophy I or higher.

Compounds of substituted n-(1h-indazol-4-yl)imidazol [1,2-a]-3-carboxamide as cfms inhibitors

Invention relates to novel formula I compounds and their pharmaceutically acceptable salts, which are cFMS inhibitors and are useful in treatment of bone diseases, cancer, autoimmune disorders, inflammatory diseases, cardio-vascular diseases and anaesthetics. Invention relates to versions of method of obtaining said compounds, pharmaceutical composition and method of treating bone diseases on their basis. In general formula

Method of preventing postoperative complications of joint endoprosthetics

Invention relates to medicine, namely to traumatology and orthopaedics, and can be applied for prevention of postoperative complications of joint endoprosthetics. For this purpose after installation of endoprosthesis elements napkin with collagen soaked with antibiotic is laid into wound, with further wrapping of joint fragments of bones. Edge of napkin is tightly introduced on the entire perimeter between each element of implant and adjoining bone.

Method of obtaining porous chitosan calcium phosphate-containing sponges for filling bone defects

Described is a method of obtaining a composite chitosan-based material, which contains aspartic or glutamine amino acids in a quantity from 2 to 5 wt %, as well as calcium phosphates with a ratio of Ca/P from 1.0 to 1.67. The method consists in barbotage through a suspension of calcium phosphates, obtained in situ in a solution of chitosan and aspartic or glutamic acid, with the following lyophilic drying of the foamed products. Porous matrices can be applied in dentistry, maxillofacial surgery, osteoplastic surgery as implants in the treatment of bone tissue defects.

Blocking anti-dkk-1 antibodies and applications thereof

Invention refers to immunology. Presented are anti-Dickkopf 1 (anti-Dkk-1) antibodies and their functional fragments specified among the antibodies: 1) containing CDR1 VH containing the amino acid sequence SSYAIS, SYAIS or GFTFSSY; CDR2 VH containing the amino acid sequence SVSGTGLGFGTYYPDSVKG or SVSGTGLGFGTY; and CDR3 VH, containing the amino acid sequence TSLENYAFDY or SLENYAFDY; and CDR1 VL containing the amino acid sequence RASESVDDFGISFIN; CDR2 VL containing the amino acid sequence AGSKQGS; and CDR3 VL containing the amino acid sequence QQLKEVPPT; and 2) the antibodies disclosed in Table 4 presented in the application materials. Described are: nucleic acids coding the above antibodies or their functional fragments; expression vectors containing the above nucleic acids; and cells used for expression of the above antibodies or their functional fragments and containing the above expression vectors. Presented is a method for producing the antibody or its functional fragment involving the stage of culturing the above expression cell. Disclosed is a composition possessing Dkk-1 binding activity, containing the antibody or its functional fragment in a therapeutically effective amount and a pharmaceutically acceptable excipient, thinner or carrier.

Pyrazole pyridine derivatives as nadph-oxidase

Invention relates to the field of organic chemistry, namely to novel derivatives of pyrazole pyridine of formula , as well as to its tautomers, geometrical isomers, enantiomers, diastereomers, racemates and pharmaceutically acceptable salts, where G1 represents H; G2 represents -CHR1R2; R1 and R2 independently on each other are selected from H; C1C6-alkoxy-C1C6-alkyl; C1-C6-alkyl; optionally substituted phenyl; optionally substituted phenyl-C1-C6-alkyl; optionally substituted morpholine-C1-C6-alkyl; or -CHR1R2 together form a ring, selected from an optionally substituted C3-C8-cycloalkyl and substituted piperidine; G3 is selected from an optionally substituted C1C6-alkoxy -C1-C6-alkyl; C1-C6-alkyl; substituted phenyl; substituted phenyl-C1C6-alkyl; G4 is selected from a substituted acyl-C1C6-alkyl, where acyl represents a group -CO-R and R stands for H or morpholine; optionally substituted C1-C6-alkyl; optionally substituted phenyl or indene; substituted phenyl-C1-C6-alkyl; optionally substituted pyridine- or furanyl-C1C6-alkyl; morpholine- or piperidine-C1-C6-alkyl; G5 represents H; where the term "substituted" stands for the groups, substituted with 1 to 5 substituents, selected from the group, which includes a "C1-C6-alkyl," "morpholine", "C1-C6-alkylphenyl", "di-C1-C6-alkylamino", "acylamino", which stands for the group NRCOR", where R represents H and R" represents a C1-C6-alkyl, "phenyl", "fluorine-substituted phenyl", "C1-C6-alkoxy", "C1-C6-alkoxycarbonyl", "halogen". The invention also relates to a pharmaceutical composition based on the formula (I) compound and particular compounds.

Method for non-invasive treatment of legg's disease

Orthopaedic unload is accompanied with prescribing a therapeutic diet promoting weight reduction and adequate feeding of calcium and vitamins C, D, E, K.That is combined with the oral administration of Fosamax® tablets 70 mg once a week for 6 months, Arthrodarin® capsules 50 mg in the morning and evening for 4-6 months and nasal sprayings of Miacalcic® 200 International Units/day in cycles of 2 weeks every 2 weeks for 4-6 months. What is also used is Milgamma® solution for intramuscular injections 2 ml a day, at least 10 times, with a pause of 1 day. Alflutop® 2 ml a day is injected intramuscularly daily within at least 20 days. That is combined with a therapeutic course including 8-10 therapeutic sessions each of which consists of the two stages of procedures following each other. The first of this stages involve the successive one-day abdominal decompression of the lower body from the waist down, pneumocompression massage of legs, manual and vacuum massages. The exposure segments are: hip joints - lateral surface of hips, gluteal region and paravertebral area L2-L5, cervical segment - paravertebral area C7-T1 and sacral bone. A preferred pause between the above procedures is no more than 10-15 minutes. Thereafter, the first stage of the therapeutic session is completed by conducting a hirudotherapy with the use of no more than 8 medicinal leeches per one session to be placed on the cervical paravertebral area C7-T1 and lumbar paravertebral area L2-L5, sacral bone, tail bone, abdomen within the liver, lower abdomen, painful hip segments and/or segments discoloured after the massage. Each therapeutic session is completed by successive procedures of the second stage with a pause of at least 3 days. A magnetic therapy and a barolasertherapy cover the segments: hip joints - lateral surface of hips, gluteal region and paravertebral areas L2-L5. A phonophoresis with the used of karipain gel covers the gluteal, knee and hip segments. Thereafter, 24 hours later the therapeutic session is repeated depending on the patient's state no more than 10 times. That is followed by doing therapeutic physical exercises in the swimming pool within at least 10 days. Kartalax® peptide preparation 1-2 ml in the concentration of at least 100 mcg in 1 ml diluted together with Tymalin® 10 mg is administered daily once a day for 10 days. After the injections are completed, peptide Vezugen® capsules 0.2 g are orally administered in the morning and in the evening 10-15 minutes before meals for 30 days. After the continuous and single course of Fosamax® and nasal sprayings of Miacalcic® are completed, 1-2 months later Osteogenon® tablets 830 mg are administered daily in a dose of 2-4 tablets 2 times a day, and Arthrodarin® capsules are also taken in a dose of 50 mg in the morning and in the evening for 4-6 months. The oral administration of the last-mentioned two preparations is repeated at least three months later.

Method of treating proximal humeral injuries

Invention refers to medicine, namely to traumatology and orthopaedics, and can be used for treating proximal humeral injuries. That is ensured by three-staged complex therapeutic actions. At the first stage, setting of fracture and reduction of humeral head dislocation is followed by immobilising an extremity by continuous twenty-four hour brace fixation of the proximal humerus with Desault's bandage for the period of 4 weeks. From the first therapeutic day, the patient does daily 30-minute therapeutic exercises, including isometric, static and ideomotor exercises to strengthen his/her arm muscles and to improve the circulation. That is combined with a complex reparative drug therapy. At the first stage, the anti-inflammatory preparation Arthrofoon is administered orally, while vasodilators improving nicotinic acid, trental or complamin microcirculation are injected intramuscularly daily for 10 days. The enzymatic preparations Wobenzyme or Flogenzyme are also administered in a dose of 3 tablets three times a day for 3-4 weeks. The second stage starting two weeks after the beginning of the treatment involves electric stimulation (ES) by exposing the collar and shoulder muscles from the involved side for 30 minutes to electric signals generated by an electric myostimulation device. The ES procedure requires the patient to perform 15-minute active motions by a healthy arm, and for the following 15 minutes the patient is expected to tense and relax alternatively the muscles from involved side. The therapeutic exercises are also done. The drug treatment regimen of the second stage implies administering the preparations Calcemin or Calcemin Advance for six months. That is combined with 10 daily intramuscular injections of the preparation Milgamma 2 ml. At the third stage 4 weeks after the beginning of the treatment, control X-ray imaging is followed by removing the brace. Accompanied by the reparative drug therapy continued, the complex therapeutic actions provide local injection therapy in number of 8-10 daily procedures. The biologically active reflex areas nearby the involved joint are pre-exposed to focused red laser light, and the mixed preparations Alflutop, or other chondroprotector, vitamin B12, Contrykal or Lidase, Lidocaine are injected in the same areas. Two weeks after the brace has been taken off, the patient keeps doing the therapeutic exercises twice a week continuously. The drug therapy and local injections are repeated six months later. The brace is further required for the following year if the patient is supposed to bear occupational or sports physical loads.

Method of treating mandibular fractures

Invention relates to medicine, namely to traumatology of the maxillofacial area, and can be applied for the treatment of mandibular fractures. For this purpose the reposition and fixation of bone fragments by means of osteosynthesis or dental splints are carried out. After the reposition and fixation of bone fragments, diluted with physiological solution or the local anaesthetic botulinum toxin A - Botox or B Myoblock is introduced once into the muscles, participating in the displacement of mandible fragments. The preparation is introduced with the distribution of the total volume and maximally allowed quantity of units by 20% in the area of muscle fixation to the bones and by 80% into the zone of the highest electric activity of the muscles, verified by the method of electromyography.

Siglec-15 antibody

Invention refers to biotechnology and immunology. What is described is a pharmaceutical composition used for treating and/or preventing pathological bone metabolism and containing this antibody. The invention can be used in medicine.

Method of treating sternomediastinitis

Invention refers to medicine, namely to surgery, and can be used for treating sternomediastinitis. That is ensured by introducing a therapeutic mixture prepared ex tempore containing a broad-spectrum antibiotic tropic to bone tissue in a half a compendially recommended average therapeutic daily dose, 1 ml of lidase 32 thousand units, 1 ml of a lincomycine solution in a dose of 0.3 g, 1 ml of ketorolac tromethamine in a dose of 0.03 g, 1 ml of dexamethasone solution in a dose of 0.004 g, 1 ml of a 10% lidocaine solution and 5 ml of a 40% glucose solution. The therapeutic mixture is administered into interspinous ligaments of the spinal column at Th2-Th3, Th3-Th4, Th4-Th5, at a depth of 1.5-2 cm in a dose of 3 ml into each injection point into a patient lying on his/her side with bringing the knees to the stomach and bending the head as forward as possible. The length of treatment makes 12-14 days with the first 3 injections performed daily; the residual injections - every second day, 8-9 injections in total.

Combination preparations with cytokine antagonist and corticosteroid

Group of inventions refers to treating arthropathies, such as arthrosis and inflammatory loss of cartilage, tendon disorders and/or degenerative spine diseases. What is presented is a pharmaceutical composition for the above application, containing a corticosteroid and a cytokine antagonist - a natural or recombinant protein of interleukin IL-1Ra antagonist, particularly orthokine or anakinra, and optionally a growth factor; the composition is injectable into an injured nerve root, or into an injured intervertebral disk, or into their local context, or for intraarticular injection. There are presented: a kit comprising the pharmaceutical composition with the above cytokine antagonist and optionally the growth factor, and the pharmaceutical composition with the corticosteroid; using the above cytokine antagonist and optionally the growth factor for preparing the pharmaceutical composition to be used in combination therapy together with the corticosteroid for the above application; using the corticosteroid for preparing the pharmaceutical composition to be used in combination therapy with the above cytokine antagonist and optionally the growth factor for treating the above arthropathies, tendon disorders and/or degenerative spine diseases.

Method for osteoanagenesis in experiment

Invention refers to medical and veterinary traumatology, surgery and concerns treating various bone injuries, particularly fractures and fissured fractures. That is ensured by fixing injured bone fragments with a plaster splint or a polymer bandage. An aqueous solution containing 1-hydroxyethylene diphosphonic aicd in an amount of 1.80-2.06 g/l, anhydrous calcium chloride in an amount of 1.44-2.22 g/l, gadolinium (III) nitrate hexahydrate in an amount of 0.30-0.40 g/l, dysprosium (III) chloride hexahydrate in an amount of 0.038-0.076 g/l is introduced into the fracture; pH of the solution is 7.3-7.8. Before administering into the fracture, the above agent is heated up to 30-100°C, kept at this temperature for 1-48 hours, and cooled to room temperature.

Method for bone defect plasty

What is applied is a stocking coating of an autogenous bone with a patient's platelet-rich plasma. Bone marrow aspirate from the patient's ilium and/or mesenchymal stromal cell autoculture prepared of the aspirate by culturing in vitro are injected under the coating layer into the autogenous bones. The autogenous bones are placed tightly in the bone defect to cover the defect area with adjacent soft tissues.

Method for surgical treatment of ununited fractures and false joints of cylindrical bones in shortage of soft tissue in projection of ununited fractures and false joints

Invention relates to medicine and specifically to trauma surgery and orthopaedics, and can be sued for surgical treatment of ununited fractures and false joints of cylindrical bones when there is a shortage of soft tissue. The method involves, 5-6 days before an operation, performing needle biopsy of bone and soft tissue fragments from the damage centre of the cylindrical bone and determining presence and nature of obligate intracellular viral infection (OIVI). Super-selective angiographic analysis of the microvascular channel to the capillary link is also performed. Valtrex is administered to the patient 2-4 days before the operation in a dose of 500 mg twice a day. Further, the method involves performing osteosynthesis or re-osteosynthesis with resection of the ends of bone fragments, opening marrowy canals, bone stimulation and batting the space of the bone defect with a gel-like nanostructured composite implant. In the presence of OIVI, resection of bone fragments is carried out in a larger volume until the onset of "pinpoint bleeding", i.e. to areas with satisfactory intrabone blood supply. The composite implant contains thrombocyte-rich autoplasma, mixed in ratio of 1:(1-2) with granules of a complex alloplastic preparation (CAP) based on hydroxyapatite which contains 50-60 wt % collagen. The composite implant also contains either 0.08-2.8 wt % colloidal solution of nanoparticles of zero-valent silver metal Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, or 5-12 wt % nanoparticles of said metals in dry form. The nanoparticles have size of 2-40 nm. A colloidal solution of said nanoparticles or colloidal nanoparticles of said metals in dry form is added to the CAP granules. Further, the prepared granules of the gel-like complex alloplastic preparation are laid in a selected ratio on the layer of thrombocyte-rich autoplasma, without mixing, for subsequent transfer into the bone defect space. In case of performing resection of bone fragments in a larger volume until the onset of "pinpoint bleeding", corticotomy is further performed on the cylindrical bone being operated on, with subsequent distraction of the bone regenerate using any existing method. Further, the bone fragments are repositioned, followed by metallo-osteosynthesis. Before wound suturing, the surface of the area with shortage of soft tissue in the projection of the ununited fracture and false joints is covered by a semi-permeable flexible plate made of the complex alloplastic preparation based on hydroxyapatite, which contains 50-60 wt % collagen. The plate has thickness of 0.25-1.2 mm. The surface area of the plate is 10-20% greater than the area with shortage of soft tissue in the corresponding projection. The part of the erythrocyte mass remaining from preparing the thrombocyte-rich autoplasma and the plasma are returned into the bloodstream of the patient by intravenously using a drip during the surgical procedure or in the early post-operation period. After the operation, valtrex is administered to the patient in a dose of 500 gm once a day for two weeks and then in a dose of 500 mg every other day for two weeks.

Method for selection using g protein-coupled receptors

Invention relates to biotechnology, specifically PTH receptor agonists, and can be used in medicine. A polypeptide of formula PTH(1-X)/PTHrP(Y-36) is constructed, where denotes an integer between 11 and 18, and Y=X+1, where PTH(1-X) is an amino acid from 1 to X of the human PTH sequence (SEQ ID NO:5) and PTHrP(Y-36) is an amino acid from Y to 36 of the human PTHrP sequence (SEQ ID NO:6). The polypeptide contains one or more of the following mutations in the PTH(1-X) sequence: Ala in position 1, Ala or Aib in position 3, Gin in position 10, Arg or homoarginine in position 11, Ala in position 12, and Trp in position 14. The obtained polypeptide is used to repair fractures, treat hypoparathyroidism, hyperphosphatemia, tumoral calcinosis, osteoporosis, osteomalacia, arthritis, thrombocytopenia, as well as increase stem cell mobilisation in a subject.

Biocompatible, biodegradable porous composite material and method of producing said material

Biocompatible, biodegradable porous composite material contains chitosan and hydrosilicate filler in amount of 0.05-10% of the weight of chitosan and has a system of through pores with size of 5-1000 mcm. The method of producing the material involves mixing hydrosilicate filler, which is pre-dispersed in an aqueous medium with pH=5-7 in an ultrasonic field with frequency v=20-100 kHz for 5-60 minutes, with chitosan in an amount which corresponds to its concentration in the solution of 1-4 wt %, the amount of the filler being equal to 0.05-10% of the weight of chitosan; the obtained mixture is then intensely mixed at temperature of 20-50°C for 20-60 minutes; concentrated acetic acid is added in an amount which enables to obtain, in the mixture of the aqueous solution, acetic acid with concentration of 1-3%; the mixture is intensely mixed at temperature of 20-50°C for 20-250 minutes and then cooled to temperature of -5 to -196°C; the solvent is removed in a vacuum; the obtained end material is treated with a neutralising agent, washed with water to pH=5-7 and then dried.

1-cyanocyclopropyl derivatives as cathepsin k inhibitors

Claimed invention relates to compounds of formula (I) where values of substituents are given in description, possessing inhibiting activity with respect to cathepsin K as well as to pharmaceutical compositions for treating diseases, associated with cysteine protease activity and to methods of inhibiting cathepsin K in mammals, requiring such treatment by introduction of efficient amount of compound to mammal.

Method of treating bone cancer

Group of inventions relates to medicine, namely to oncology, and can be used for treatment of subject's bone tumour. For this purpose bone tumour in subject is, at least, partially ablated. Area, adjacent to the bone section, where tumour was, at least, partially ablated, is brought into contact with gel, containing taurolidine, taurultam, their mixture or their solution, which is in equilibrium. Also claimed is prevention of development of bone tumour recurrence in subject.

Tetrahydrofuro(3,2-b)pyrrol-3-ones as cathepsin k inhibitors

Present invention refers to compounds of formula (l) and their pharmaceutically acceptable salts wherein X represents CH or N; one of R1 and R2 represents H and the other one is specified in OR6, SR6, Me, Et and SOR8; R3 is specified in tert-butylmethyl, sec-butyl, tert-butyl, cyclopentyl and cyclohexyl; R4 cyclopentyl C1-8alkyl optionally substituted by one C1-6alkoxy group; or C3-8cycloalkyl optionally substituted by one C1-6alkoxy group; R6 represents C1-8alkyl; and R8 represents C1-8alkyl, as well as to based pharmaceutical compositions and applying them as cathepsin K inhibitors and for analysing the cathepsin K inhibitors specified above.

Prolonged slow release pharmaceutical composition containing water suspension of bisphosphonate

Invention refers to a pharmaceutical composition effective for injections in the form of a water suspension for prolonged release of a bisphosphonate agent. Said pharmaceutical composition contains a combined dispersion complex containing a salt of a bisphosphonate agent and a salt of pentavalent phosphorus oxoacid, and the complex has solubility in physiologic saline less than 0.05 wt % at bisphosphonic acid. The invention also refers to a pharmaceutical composition effective for injection which contains the combined dispersion complex containing a calcium salt in the amount less than 50 wt %, a calcium salt of pentavalent phosphorus oxoacid with the solid substance having an average particle size 1-100 mcm, the calcium to phosphorus mass relation is equal to 0.5-3; and the composition has pH equal to 6-9.5 if the complex is suspended in an aqueous medium. The invention also refers to a method of treating or preventing of bone diseases in patients with, e.g. osteoporosis, implying the intramuscular introduction of said compositions in a patient's body.

Azabenzofuranyl compounds and methods of use

Invention relates to azabenzofuranyl compounds of formula I and salts thereof, where: Z1 denotes CR1, Z2 denotes N, Z3 denotes CR3, Z4 denotes CR4, R1, R3 and R4 are independently selected from H, halogen, CN, -(CR14R15)nC(=Y)OR11, - (CR14R15)nOR11, C1-C12 alkyl; W denotes or R5 and R6 are independently selected from H or C1-C12 alkyl; X1 is selected from R11, -OR11 and -S(O)2R11; if X1 denotes R11 or -OR11 from X1 and -R5 optionally taken together with a nitrogen atom with which they are bonded form a 4-6-member saturated or unsaturated ring containing 0-2 additional heteroatoms selected from O, S, where said ring is optionally substituted with one or more groups selected from oxo, -(CR19R20)nNR16R17, -(CR19R20)nOR16, (CR19R20)nS(O)2R16 and R21; X is selected from aryl, where said aryl is optionally substituted with one or more groups selected from halogen, CN, -Si(C1-C6alkyl), -(CR19R20)nOR16, -(CR19R20)nSR16, C1-C12alkyl; R11, R12 and R13 independently denote H, C1-C12alkyl, aryl, azetidine, pyrrolidinyl, piperidinyl, tetrahydropyranyl; R14 and R15 are independently selected from H or C1-C12 alkyl; n is independently selected from 0, 1; Y independently denotes O; where each of said alkyl, alkenyl, aryl and heteroaryl from R1, R2, R3, R4, R5, R6, X1, X2, R11, R12, R13, R14 and R15 is independently and optionally substituted with one or more groups independently selected from -(CR19R20)nC(=Y')OR16, -(CR19R20)nNR16R17, -(CR19R20)nOR16, -(CR19R20)nNR16C(=Y')R17, -(CR19R20)nNR16C(=Y')OR17, - (CR19R20)nNR17SO2R16 and R21; each R16, R17 independently denotes H, C1-C12 alkyl, C2-C8alkenyl, aryl, or pyridinyl, where said alkyl, alkenyl or aryl is optionally substituted with one or more groups selected from -OH; R19 and R20 are independently selected from H, C1-C12 alkyl; R21 denotes C1-C12 alkyl, aryl, imidazolyl, pyridinyl, pyrazolyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, or 2,2-dimethyl-1,3-dioxolanyl; each Y' independently denotes O. The invention also relates to specific compounds, a pharmaceutical composition based on the disclosed compounds, a method of inhibiting anomalous cell growth or a method of treating hyperproliferative disorders, inflammatory diseases and other diseases.

Method of treating aseptic necrosis of femoral head

Invention relates to medicine, in particular, to traumatology and arthrology, and can be used for non-surgical treatment of aseptic necrosis of femoral head. Method includes performing injections of 2-4 ml of into intra-articular fissure of hip hoint under ultrasonic control. Injections are made in courses 2-5 times per week. Course duration is not shorter than two weeks.

Method of treating long bone fractures in iodine deficiency diseases

Invention refers to medicine, namely to traumatology, and concerns treating long bone fractures in iodine deficiency diseases. That is ensured by introduction of 1 % ATP sodium salt, Iodomarin 200 1 tablet once a day, the preparation "Sea Calcium" with vitamin D3 2 tablets 3 times a day from the first day of treatment, and on the 14th day after reduction and stabilisation, the preparation Chondrolone 1.0 ml is injected intramuscularly once a day for 3-4 weeks.

Neurotisation and protection agent

Invention refers to chemical-pharmaceutical industry, and concerns a EP2 agonist which exhibits the EP3 agonist action, and induce a neurotising and/or protective effect and thereby is effective as a therapeutic agent for a peripheral nerve disease, such as lower and upper motor neuron disorder, nerve root disease, plexopathy, brachial plexus compression syndrome, peripheral neuropathy, neurofibromatosis and nervomuscular conduction disease.

Method of treating fractures of long tubular bones

Invention relates to medicine, namely to traumatology, and deals with treatment of fractures of long tubular bones in case of iodine-deficiency diseases. For this purpose from the first day of treatment introduced are: 1% solution of sodium salt ATP, iodomarin 200 in dose 1 tablet 1 time per day, preparation "Sea calcium" with vitamin D3 in dose 2 tablets 3 times per day, and on the 14-th day after matching and fixation of fragments introduced is medication chondrolon in dose 1.0 ml intramuscularly 1 time per day during 3-4 weeks.

Substituted propanamide derivative and pharmaceutical composition containing such derivative

Claimed invention related to novel substituted propanamide derivatives of general formula (I'), as well as their pharmaceutically acceptable salts and based on them pharmaceutical compositions, which possess suppressive activity against bone resorption and reduction of bone density, reducing concentration of calcium in blood. Claimed invention also relates to application of compounds of general formula (I') or their pharmaceutically acceptable salts and based on them pharmaceutical compositions for production of medications. Values m, n and R5-R9 substituents are given in invention formula.

Ibandronate polymorph b

Invention relates to a new crystalline polymorph of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with formula I, which is characterised by x-ray powder diffraction pattern with characteristic peaks at angles 2-theta: 9.7°, 12.2°, 14.4°, 16.8° and 25.8°, IR-spectrum with characteristic peaks, cm-1: 3679, 3164, 2955; 2854, 1377, 1290, 1157, 1093, 1068, 1035, 965, 951, 933, 905, 761 and 723, as well as a vibrational Raman spectrum with characteristic peaks, cm-1: 2968, 2951, 2928, 2887, 2849, 1441, 1308, 1136, 1056, 1023, 954, 907, 839, 762 and 678. formula I.

Dosage forms of risedronate

There are described oral dosage forms of risedronate containing safe and effective amount of a pharmaceutical composition containing risedronate, a chelating agent and an agent for effective delayed release of risedronate and the chelating agent in small intestine. The pharmaceutical composition is directly released in a small intestine of a mammal with ensuring pharmaceutically effective absorption of bisphosphonate together with or without food or drinks. Present invention essentially reduces interaction between risedronate and food or drinks which leads to that the active component of bisphosphonate becomes inaccessible to absorption. Thus, the final oral dosage form can be taken with and without food. Further, present invention covers delivery of risedronate and the chelating agent in a small intestine, essentially reducing irritation of upper gastrointestinal tract associated with bisphosphonate therapy. These advantages simplify previous, complicated regimens and can lead to more complete observance of the bisphosphonate therapy regimen.

Porous composite materials based on chitosan for filling of bone defects

Invention is related to the field of medicine and is related to composite materials for plastic reconstruction of damaged bone tissues. Invention represents porous composite material on the basis of chitosan for filling of bone defects, which contains chitosan, tricalcium phosphate and differs by the fact that it contains chitosan with molecular weight of more than 300000 g/mole, additive of ammonium carbonate, and calcium-phosphate fillers used are substances in the form of powder or granules with particle size of 1-1000 mcm, selected from the following group: brushit, monetite, tetracalcium phosphate, hydroxyapatite, carbonate hydroxyapatite, or their mixtures, at the same time components of material are available in a certain ratio.

Method of integrated treatment of spinal osteomyelitis with applying regional lymphotropic therapy

Invention concerns medicine, namely traumatology, orthopaedics and can be used for treatment of spinal osteomyelitis. That is ensured by antibacterial, immunocorrective, detoxication therapy, and surgical sanation and resection of the inflammation centre, and autogenous bone grafting of the cavity, and stabilisation with a plate of the system AESCULAP "MACS". It is combined with regional lymphotropic therapy according to the schedule dry Lydasa 64 st. units, 2% lidocaine 2 ml, lincomycin 2 ml. The mixture is introduced every 48 hours in number of 5 injections in the preoperative period and 7 injections in the postoperative period.

Polymorphic modification of a ibandronate

Invention relates to a new crystalline polymorphic modification of a monohydrate of mon-sodium salt of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid (ibandronate) of formula 1, used for controlling hypercalcemia. formula 1.

Pharmaceutical products containing biphosphonates

There is disclosed pharmaceutical product as prepared solution. The pharmaceutical product comprises a reservoir filled with dissolved zoledronic acid or its pharmaceutically acceptable salt. At least the internal surface of said reservoir contains plastic material that is polyolefin. The product is exposed to thermal sterilisation, preferentially to moist thermal sterilisation. Besides the product can contain a buffer component, preferentially the buffer organic base. Additionally, the product can contain an isotonic component, preferentially mannitol. The invention provides product sterilisation at high temperature 121°C during 150 minutes without visible deformations and damages of sealed integral reservoir, as well as decomposition of pharmaceutical substance.

Bone loss treatment and prevention method

Compound contacts with 15-lipoxygenase and tested for activity for 15-lipoxygenase inhibition.

Method of aseptic whirlbone necrosis and perthers disease treatment

Invention concerns medicine, particularly orthopedics and extracorporal treatment methods, and can be applied in aseptic whirlbone necrosis and Perther disease treatment. Method involves venous blood sampling in amount of 300 ml with further blood separation into erythrocyte mass and plasma. Obtained erythrocyte mass is diluted by 200 ml of 0.9% physiological solution and administered intravenously to patient. 100 ml or patient's plasma is placed in thermostat and incubated for 20 minutes at 37°C. Further 20 mg of vasoprostan medicine is added to incubated plasma, and obtained mix is administered to patient by drop infusion for 1.5-2 hours once a day for 10 days.

Method of prevention of postoperative osteomyelitis

For prevention of postoperative osteomyelitis use composition consisting of antimicrobial substances, dissolved in high-molecular polyvinylpyrolidone with molecular mass of 1 million. The composition is administered using a syringe into the medullar channel and in the intermuscular spaces surrounding a bone, on a measure of sealing of soft tissues after operation. Invention allows to give antimicrobial activity to tissues surrounding wound for long time at the expense of slow biodegradation of polyvinylpyrolidone and long-term diffusion of antimicrobial substances from a composition in a tissue.

Amorphous alendronate monosodium, methods of production, based pharmaceutical composition and method of inhibition of bone resobrtion

Invention refers to method of production of amorphous alendronate monosodium and to solid pharmaceutical composition having property to invoke bone bulk expansion and containing therapeutically effective amount of amorphous alendronate monosodium, produced by stated method. Method of production of amorphous alendronate monosodium includes solvent removal from alendronate monosodium solution using spray drying.

Pharmaceutical formulation applied for prevention and treatment of bone tissue resorption of any etiology, transdermal delivery and treatment technique

Given invention refers to pharmaceutical field, specifically to pharmaceutical formulation of gel dosage form applied for prevention and treatment of osteoporosis including as an active component bisphosphonate incorporated in phospholipid vesicles generated from lipid and hydrophilic phases, including components in the following proportions, mass %: bisphosphonate 0.01-2.0; egg lecithin 1.0-6.0; pine essence 0.05-0.2; camphor oil 0.01-1.0; olive oil 0.01-5.0; vitamin E 0.01-0.15; vitamin D 0.01-0.2; vitamin F 0.2-0.4; carbopole 0.4-0.6; NaOH 0.42; glycerol 2.0-4.0; nipagine 0.3; nypazole 0.1; water and others. In addition invention refers to treatment of bone tissue resorption of any etiology and osteoporosis for patients suffering from gastrointestinal disturbance with this composition.

Osteoprotegrin, its application for preparation of pharmaceutical composition (variants), production of food substance (variants) and fodder, food substance, fodder and pharmaceutical composition for prevention and treatment of disorders related to bone remodeling, and/or immune disorders

This invention is related to biotechnology, to be more precise, to preparation of proteins out of milk, and may be used for prevention or treatment disorders related to metabolism in bones and immune function. Osteoprotegrin is prepared out of human or cow milk and has glycolysis profile that produces polypeptide with molecular mass of approximately 80, 130 and 200 kilodaltons. Prepared protein is used in structure of food substance and pharmaceutical composition for prevention or treatment of disorders related with bone remodeling, and/or immune disorders. Also prepared protein is added to make fodder.

Method for treating and preventing the loss of bony tissue

The present innovation deals with treating and preventing the loss of bony tissue and/or increased development of bony tissue. For this purpose it is necessary to apply 15-lipoxygenase inhibitors. These molecules could be introduced either individually or in combination with agents that inhibit the resorption of bony tissue or additional agents that regulate calcium resorption out of bony tissue or increase the accumulation of bony tissue. The innovation enables to widen the assortment of medicinal preparations for treating diseases associated with the loss of bony tissue, such as osteoporosis, osteoarthritis, Paget's disease and those of periodontium and, also, the fractures.

Osteoplastic composite material

Material comprises deproteinized allobone granules as filler, the granules being at least 1 mm large, and hydrophylic dimethylacrylate as monomer. Bone cement, filler and monomer are taken in 1:1:0.5 proportion, respectively.

Analogs of vitamin d

Invention relates to novel triaromatic compounds, namely, analogs of vitamin D of the general formula (I): wherein values R1, R2, R3, X and Y are given in claim 1 of the invention claim. Also, invention relates to using these compounds in pharmaceutical compositions designated for treatment of the following diseases: (1) dermatological diseases associated with differentiation disturbance or proliferation of keratinocytes or sebocytes; (2) keratinization disorders; (3) dermatological diseases associated with disturbance of keratinization with inflammatory and/or immunoallergic components; (4) inflammatory diseases that don't represent keratinization disturbance; (5) cutaneous or epidermic expansion; (6) dermatological disorders, for example, vesicle dermatosis and collagenosis; (7) photoinduced or senile skin ageing, or for decreasing photoinduced pigmentations and keratosis, or any other pathologies associated with senile or photoinduced ageing; (8) skin healing and scar disturbances; (9) lipid function disturbances, such as acne hypersteatosis, simple seborrhea or seborrheic eczema; (10) dermatological diseases with immunologic component. Also, invention relates to cosmetic using the cosmetic composition for body and hair hygiene.

Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using

Invention relates to drugs used in prophylaxis and treatment of the locomotor system, in particular, degenerative-dystrophic joint and backbone diseases. Invention proposes a pharmaceutical composition normalizing metabolism in osseous and cartilage tissues and comprising the effective amount of peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] as an active component, and pharmaceutically acceptable carrier. Invention proposes peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] possessing the biological activity manifesting as normalization of metabolism in osseous and cartilage tissues. Invention proposes a method for prophylaxis and treatment of locomotor system by normalization of metabolism in osseous and cartilage tissues involving administration in a patient of a pharmaceutical composition containing as an active component peptide alanyl-glutamyl-aspartic acid of the general formula: H-Ala-Glu-Asp-OH of the sequence 1 [SEQ ID NO:1] in the dose 0.01-100 mcg/kg of the body mass for at least once per a day for time necessary for achievement of the therapeutic effect. Invention can be used as agent normalizing metabolism in osseous and cartilage tissues.

Method for optimizing bone reparative regeneration

Method involves preparing bioantioxidant Thiophan solution with alpha-tocopherol oil solution taken as base taken in Thiophan 5 mg and alpha-tocopherol 5 ml proportion. The bioantioxidant solution is introduced at a dose of 3 mg/kg of body weight into intramedullary canal of damaged bone through polyvinylchloride catheter once a day, daily during 4 days, then, every other day. Total treatment course is 10 injections long.

Composition for bone tissue treatment in damages of inflammation etiology

Claimed composition contains nutrient medium, 10 % serum of cow embryo, human fibroblast diploid cells and gel filler in the next component ratio (in 1 ml): nutrient medium 0,01-0,9; 10 % serum of cow embryo 0,001-0,2; suspension of human fibroblast diploid cells 1x105- 5x109 cells; and balance: gel filler. As human fibroblast diploid cells composition contains human fibroblast diploid cell strain from embryo lung tissue for substitutive therapy or human fibroblast diploid cell strain from embryo skin-muscle tissue for substitutive therapy. As gel filler 5 % polyethylene oxide may be used.

Method for stimulating osteogenesis at fractures of tubular bones

The innovation suggested deals with treating osseous-destructive diseases of motor system. Thus, in case of the fractures of tubular bones it is necessary to introduce 0.1-0.2%-angiogenin solution isolated due to ultrafiltration out of cow's milk once into the fracture site. The innovation provides improved efficiency of stimulation at excluding the risk for infecting, allergic reactions and, also, the chance fir translocation of tumor cells associated with the use of angiogenin of another origin.

Pharmaceutical compositions for peroral intake of pharmacological active substances

A solid pharmaceutical composition contains therapeutically efficient quantity of peptide as a pharmacological active substance, crospovidone or povidone, and an agent that favors peptide's introduction. A peptide is being calcitonin, salmon's calcitonin preferably. The above-mentioned agent is being 5-CNAC (N-(5-chlorsalicyloyl)-8-aminocaprylic acid), preferably, disodium salt 5-CNAC. The composition suggested provides high biological availability of peptides, such, for example, as calcitonin.

Medicinal preparation for treating osteonecrosis and for treating patients at risk of osteonecrosis development

The present innovation deals with applying biphosphonate for treating osteonecrosis and/or osteonecrosis dissecans. This medicinal preparation could be additionally applied for preventing the development of osteonecrosis and/or osteonecrosis dissecans and any complications associated with both diseases. Biphosphonate acts for the decrease or prevention of severe degree of deformation and/or destruction of a bone or a cartilage and provides the chance to form new bony tissue in a patient.

New analogues of vitamin d

Invention relates to a new compound of the formula (I): wherein X means hydrogen atom or hydroxy group; R1 and R2 that can be similar or different mean hydrogen atom, (C1-C4)-alkyl; R3 means hydrogen atom, methyl group, fluorine or chlorine atom. Also, invention relates to its esters able to hydrolysis in vivo in combination with pharmaceutically acceptable acids. Also, invention relates to a pharmaceutical composition eliciting the inhibitory activity with respect to proliferation and promoting differentiation of cells and comprising the effective dose of compound of the formula (I) in common with pharmaceutically acceptable carriers and/or excipients. Also, invention relates to applying compound of the formula (I) for preparing a medicine used in treatment and prophylaxis of disease characterizing by abnormal differentiation of cells and/or proliferation of cells.